Carbamylated erythropoietin ameliorates cyclosporine nephropathy withoutstimulating erythropoiesis

环孢素(CsA)的引入提高了移植物的存活率，但会引起肾病，限制了其临床应用。为了研究CEPO的临床应用，我们接下来使用CsA诱导的肾病模型评估了CEPO的长期治疗效果。环孢素A可引起肾功能障碍，而EPO/CEPO可显著改善肾功能。EPO处理显著提高了Hb浓度，而CEPO处理既没有增加Hb浓度，也没有降低Hb浓度。这些结果提示了一种使用CEPO来保护肾脏免受CsA肾病影响的新的治疗方法。

The introduction of cyclosporine (CsA) has improved graft survival, but it causes nephropathy, which limits its clinical utility. To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a CsA-induced nephropathy model. CsA caused renal dysfunction, while EPO/CEPO administration significantly improved renal function. EPO-treatment significantly increased Hb concentration, while CEPO-treatment neither enhanced nor reduced Hb concentration. These results suggest a new therapeutic approach using CEPO to protect kidneys from CsA-induced nephropathy.